Longevity Weekly Review 2026-07-08

Week In Review

Longevity science this week continued its measurable pivot from “will it work in mice?” to “what exactly is it doing in humans, and can we prove it with the tools we have?” The clearest signal came from Retro Biosciences, whose CEO Joe Betts-LaCroix reported that the company’s first-in-human trial of an autophagy-enhancing pill for Alzheimer’s disease has cleared its dose-escalation phase without dose-limiting toxicities, with data expected in about a month (Retro Bio’s $1.8b moment: Hopes up as Alzheimer’s trial advances). The industry-side counterpart was Novartis’s stand-up of a Diseases of Aging and Regenerative Medicine division and its up-to-$550 million target-discovery deal with BioAge Labs, the first time a top-five pharma has organized a franchise explicitly around aging biology (Why longevity might be biopharma’s next big thing).

Behind those business milestones sits the machinery that makes them legible. Nature Aging published organ-specific proteomic aging clocks trained on 43,616 UK Biobank participants and validated in Chinese and US cohorts, giving the field a portable way to say “your brain is aging faster than your liver” and predict disease onset beyond standard clinical risk scores (Organ-specific proteomic aging clocks predict disease and longevity across diverse populations). This matters because the human trials now beginning — Retro’s Alzheimer’s study, Life Biosciences’ partial-reprogramming program, and the wave that follows — need short-horizon readouts, not decade-long mortality endpoints, and organ-resolved aging biomarkers are the most credible candidates.

Two mechanistic threads dominated the primary literature. The first is metabolism: a Nature Aging paper on exercise-trained older adults found that half of the age-related differences in muscle energy-metabolism gene expression simply disappear in trained older adults, and a PNAS report identified specific mitochondrial remodeling steps that carry the effect (Delayed molecular aging in exercise-trained human muscle; Mitochondrial remodeling in skeletal muscle underlies exercise-induced reversal of age-associated functional decline). The second is pharmacology mimicking that metabolism: a Cell Metabolism report showed GLP-1 receptor agonism produces body-wide multi-omic changes in aged mice that closely resemble the effects of mTOR inhibition (Body-wide multi-omic counteraction of aging with GLP-1R agonism), and an Aging Cell meta-analysis concluded that rapamycin — but not metformin — reliably mirrors caloric restriction’s lifespan extension across vertebrates (Rapamycin, Not Metformin, Mirrors Dietary Restriction-Driven Lifespan Extension in Vertebrates).

The rest of the week’s items fill in specific mechanisms: a multi-tissue transcriptomic map of the senolytic combination dasatinib plus quercetin in aged mice, a partial-reprogramming variant that pairs OSK factors with TERT to postpone senescence without pluripotency risk, and a C. elegans study restoring peroxisomal function to rescue lipid mobilization during aging. Taken together, the week reinforces a picture in which aging is not a single lever but a set of interacting metabolic, mitochondrial, and epigenetic systems — and the therapeutics moving into humans are increasingly ones with a defensible story about which lever they pull.

Items

Retro Biosciences Alzheimer’s Autophagy Trial Clears Dose-Escalation

Retro Biosciences, the Sam Altman-backed longevity company that closed a fresh round at a $1.8 billion valuation in May, reported this week that its first-in-human trial of an oral autophagy-enhancing compound for Alzheimer’s disease has completed dose escalation with no dose-limiting toxicities observed. CEO Joe Betts-LaCroix described the trial as “going super good” and said early data should be public around August 2026.

Autophagy — the cellular housekeeping process that clears misfolded proteins and damaged organelles — declines with age and is implicated in neurodegeneration. Retro’s compound is designed to reactivate this system in patients whose neurons are accumulating the amyloid and tau aggregates characteristic of Alzheimer’s. The bet is that clearing the aggregates upstream will do more than the antibody-based approaches that dominate the current Alzheimer’s pipeline.

The company positions autophagy enhancement as its lead program, but its wider ambition is broader: Betts-LaCroix has stated repeatedly that Retro’s goal is to add ten healthy years to the human lifespan. In-vivo gene therapies and cell-replacement approaches sit behind the autophagy pill in the pipeline. The Alzheimer’s trial’s importance for the longevity field is less about the specific indication than about establishing whether a small biotech built explicitly around aging biology can advance a drug through a real regulatory pathway.

Watchers of the field should note that August’s data is a safety and early-biomarker readout, not efficacy. But a clean safety profile in an elderly patient population would be a significant unlock for autophagy modulators, a class that has historically failed on tolerability.

Source: Longevity.Technology

Novartis Launches Aging-Focused Division, Signs $550M Deal with BioAge Labs

Novartis announced the formal launch of its Diseases of Aging and Regenerative Medicine (DARe) division this week, alongside a target-discovery collaboration with BioAge Labs worth up to $550 million in milestone and success payments. The move is the most concrete signal to date that top-tier pharmaceutical companies now regard aging biology as a first-class discovery platform rather than a research curiosity.

DARe is structured around the geroscience hypothesis: that intervening on the fundamental biology of aging can prevent or delay multiple age-related diseases at once, rather than treating each in isolation. BioAge’s contribution to the partnership is its human-data-driven target discovery engine, which mines longitudinal cohorts for molecular signatures that distinguish healthy agers from those on faster trajectories toward specific diseases.

The financial commitment is modest by Novartis’s standards but structurally significant. Pharmaceutical companies typically wait until a therapeutic area has demonstrated clinical proof-of-concept before organizing dedicated business units. DARe’s stand-up before any geroscience drug has been approved suggests Novartis sees the pipeline maturing quickly enough to justify a first-mover position.

For the longevity venture ecosystem, the deal validates the “sell targets to big pharma” business model that companies including BioAge, Gero, and Insilico have pursued. It also raises the ceiling on outcomes for the roughly $8.5 billion that flowed into longevity-focused startups over the past year, giving those companies plausible acquirers rather than the previous default of IPO-or-bust.

Source: Clarivate

Organ-Specific Proteomic Aging Clocks Predict Disease Beyond Standard Risk Scores

A Nature Aging paper this cycle described organ-specific aging clocks built from plasma proteomics on 43,616 UK Biobank participants and validated in Chinese (n=3,977) and US (n=800) cohorts. Cross-cohort correlations of 0.98 and 0.93 mark this as one of the most robustly generalizable aging biomarker efforts published to date.

The clocks assign each of ten organs a biological age based on the abundance of tissue-enriched proteins detectable in circulating blood. Individuals with accelerated aging of a specific organ showed elevated risk of disease in that organ years before diagnosis: accelerated brain aging predicted dementia and stroke, accelerated cardiac aging predicted heart failure, and so on. Accelerated brain aging showed the strongest link to all-cause mortality, hinting that whole-body aging trajectories may be driven disproportionately by neural decline.

Critically, the organ clocks predicted disease and mortality even after controlling for standard clinical risk factors and polygenic scores. That means they capture information about biological trajectory that current risk models miss — the kind of independent signal that could plausibly earn a place in preventive medicine over the next several years.

For the longevity therapeutics field, organ-specific clocks address a chronic problem: no drug developer wants to run a fifty-year mortality trial, but until this year the alternatives were composite clocks that gave a single number and were hard to link to any specific tissue. If a candidate rejuvenation drug can be shown to slow the plasma proteomic aging signature of, say, the liver in six months, that gives regulators and investors a much sharper handle on what the therapy is actually doing.

Source: Nature Aging

Exercise-Trained Older Muscle Reverses Half of Age-Related Energy Metabolism Changes

A Nature Aging study performed transcriptomic, lipidomic, and metabolomic profiling of skeletal muscle from young adults, sedentary older adults, and exercise-trained older adults, both at rest and after an acute bout of submaximal exercise. The headline finding: 50% of the age-related differences in energy-metabolism gene expression seen in sedentary older adults were absent in the trained group, giving their muscle molecular profiles that in many respects resembled those of young adults.

The result cuts against the framing of exercise as a modest, incremental aging intervention. In the tissue examined here, sustained training appears to reset half the molecular clock of energy metabolism — a large effect for something available without a prescription. It also reframes the interpretation of aging skeletal muscle: much of what looks like a hardwired decline is closer to a deconditioning signature that responds to sustained load.

The study also examined acute exercise responses. All age groups mounted transcriptional immune and stress-response programs after a submaximal bout, but the magnitude of the older adults’ response scaled with their fitness. Fitter older muscle isn’t just baseline-younger; it also responds to a workout more like young muscle does, suggesting the adaptive machinery itself is preserved by prior training.

The implications for geroscience are twofold. First, any drug trial claiming to rejuvenate muscle metabolism will need to control tightly for baseline fitness, or risk mistaking a lifestyle effect for a pharmacological one. Second, exercise remains the benchmark that pharmacological interventions targeting muscle aging will be measured against — and that benchmark is higher than the “modest healthy-aging benefit” framing sometimes assigned to it.

Source: Nature Aging

Mitochondrial Remodeling Identified as Mechanism of Exercise-Induced Rejuvenation

A PNAS report published in late June identified specific mitochondrial remodeling steps that underlie exercise’s reversal of age-associated functional decline in both mice and humans. The study bridges the muscle-training finding above with a concrete molecular mechanism, moving the story from “exercise resembles youth” to “here is the pathway doing the resembling.”

The team traced the effect to changes in mitochondrial network architecture — the fusion, fission, and cristae remodeling that govern how efficiently the organelle converts substrate into ATP. In aged, sedentary muscle these processes are dysregulated in characteristic ways; sustained aerobic training restored more youthful patterns and correlated with recovery of physical function. Human muscle biopsies from trained older adults showed the same remodeling signature, giving the finding a translational anchor.

The result matters for drug developers because it identifies discrete molecular targets — the machinery of mitochondrial dynamics — that pharmacological interventions could in principle engage. Compounds like urolithin A, which promote mitophagy (selective removal of damaged mitochondria), and mTOR inhibitors, which broadly regulate mitochondrial biogenesis, now have a clearer mechanistic frame in which to demonstrate whether they can reproduce exercise’s downstream benefits without requiring the exercise itself.

The pragmatic reading is that mitochondrial remodeling is emerging as a highly conserved lever on aged tissue function, and that both behavioral and pharmacological interventions may converge on it. That kind of convergence is a good sign for developing surrogate endpoints usable in shorter trials.

Source: ScienceDaily

GLP-1 Receptor Agonism Produces Body-Wide Molecular Signatures of Rejuvenation in Mice

A Cell Metabolism study performed deep multi-omic profiling of aged male mice treated with a GLP-1 receptor agonist starting at 11 months of age for 30 weeks. The treatment produced body-wide changes in transcriptome, proteome, and metabolome that broadly counteracted age-associated shifts — with striking similarity to the molecular fingerprint of mTOR inhibition, the most lifespan-extending pharmacological intervention known in mammals.

The functional side was more measured. Treated mice showed improvements on selected physical function tests, but the study did not run to death and thus makes no direct lifespan claim. The authors are careful about this: the multi-omic overlap with mTOR inhibition is suggestive, not definitive, and lifespan trials with the same molecule are the appropriate next step.

The broader context matters. GLP-1 receptor agonists (semaglutide, tirzepatide, and successors) are now taken by tens of millions of people, primarily for obesity and diabetes. If they turn out to independently modulate aging biology at the doses and durations already in widespread use, the population-level implications are substantial — and the existing safety database allows longevity-endpoint trials to be designed with a level of confidence rarely available in this field.

Ongoing human work supports this trajectory: a recent randomized trial reported that semaglutide slowed biological aging as measured by multiple validated epigenetic clocks, and the SURMOUNT-MMO tirzepatide trial has all-cause mortality and major cardiovascular events as its primary endpoint. The GLP-1 class is arguably closer than any other approved drug to a demonstration that pharmacology can move an aging clock in humans.

Source: Cell Metabolism

Rapamycin, Not Metformin, Mirrors Caloric Restriction in a Vertebrate Meta-Analysis

An Aging Cell meta-analysis compiled published lifespan data for rapamycin, metformin, and caloric restriction across vertebrate species and asked which drug most closely reproduces the effect size and dose-response signature of dietary restriction. The answer was rapamycin, unambiguously. Metformin’s lifespan-extension record across the same corpus was substantially weaker and less consistent.

This is a meaningful update for a field where the two drugs have often been discussed as parallel candidates for the first “geroscience-indicated” human approval. The TAME trial has been the flagship metformin-for-aging program for years; rapamycin has largely relied on off-label physician-directed use plus a growing body of dog-lifespan data from the University of Washington’s Dog Aging Project. This meta-analysis realigns the mechanistic priors: on the vertebrate evidence, rapamycin belongs in a category with caloric restriction, while metformin’s aging effects appear to be more modest and more context-dependent.

The finding does not settle the human question — TAME’s design assumes metformin’s benefits will show up as reduced age-related disease incidence rather than direct lifespan extension, which the meta-analysis does not directly address. But it does inform how much weight to give each drug’s mouse-lifespan data when reasoning about probability of human success.

For clinicians and patients navigating the informal longevity-medication landscape, the practical implication is that if the goal is to mimic the mechanistic signature of caloric restriction, rapamycin has the stronger vertebrate evidence base. Neither drug should be assumed safe for chronic off-label use without medical supervision, but the mechanistic priors are now clearer.

Source: Aging Cell

Multi-Omic Map of Senolytic Treatment Effects Across Tissues in Aged Mice

Researchers this week published a bulk, single-cell, and single-nucleus transcriptomic profile of the effects of dasatinib and quercetin (D+Q) — the most-studied senolytic combination in the field — across multiple tissues in aged male mice. The result is the highest-resolution atlas to date of what senescent-cell clearance actually does at the molecular level in vivo.

The study reports coherent effects on immune function, tissue fibrosis, and metabolism, with the strongest responses observed when treatment started earlier in the aging trajectory and continued for longer. Late-life short-course treatment produced smaller effects, consistent with the growing view that senolytic therapy is more valuable as a chronic disease-modifying intervention than as a rescue therapy for advanced age-related pathology.

The atlas also identifies tissue-specific responder and non-responder cell populations, addressing a longstanding gap in the field. Human D+Q trials in idiopathic pulmonary fibrosis have shown functional improvements, but until now the cellular-resolution picture of which cells were being killed and which downstream populations were adapting has been sparse.

For the clinical translation of senolytics, the practical value is guidance on trial design: which biomarkers to monitor, which tissues are most likely to show effects, and which patient populations (based on senescent-cell burden) may be most responsive. It also strengthens the case for combination approaches that pair senolytics with senomorphics or reprogramming — the atlas identifies compensatory responses that a monotherapy alone will not fully neutralize.

Source: Nature Aging

Partial Reprogramming with OSK Plus TERT Delays Senescence Without Pluripotency Risk

A study published this cycle describes a partial-reprogramming approach that combines three Yamanaka factors (Oct4, Sox2, Klf4 — the “OSK” cocktail) with the telomerase gene TERT, reporting significantly delayed cellular senescence in treated cells while avoiding the tumorigenic pluripotency risks that have dogged the four-factor OSKM approach.

The Yamanaka-factor rejuvenation program is one of the most fertile lines in longevity biology: brief pulses of the reprogramming factors can reset the epigenetic marks associated with aging without pushing cells all the way back to pluripotency, allowing them to become biologically younger while retaining their specialized function. The safety catch has been that if reprogramming runs too long or expresses too many factors, cells lose their identity and become tumorigenic.

The OSK+TERT combination addresses both edges of this safety problem. Dropping the c-Myc oncogene (the “M” in OSKM) reduces the transformation risk; adding TERT gives an independent mechanism for telomere maintenance without relying on the reprogramming factors to do that work. The result is a therapy candidate with a plausibly cleaner safety profile than earlier partial-reprogramming approaches.

The context is that Life Biosciences received the first FDA IND clearance for a partial-reprogramming therapy earlier this year, and other programs are moving toward the clinic behind it. OSK+TERT and its cousins represent the class of second-generation reprogramming therapies that will follow the pioneers — potentially with better safety margins that support broader indications, including chronic use in generally healthy adults rather than only in patients with acute organ damage.

Source: PubMed Central

Peroxisomal Function Restoration Rescues Lipid Mobilization in Aged C. elegans

Work described in a July report demonstrates that in the roundworm C. elegans, age-associated decline in peroxisomal function impairs lipid mobilization and metabolic flexibility — and that restoring peroxisomal activity reinstates metabolic resilience in aged animals. The finding highlights a lever on aging that has been comparatively neglected relative to mitochondria.

Peroxisomes are the small organelles responsible for beta-oxidation of very-long-chain fatty acids and detoxification of reactive oxygen species. Their dysfunction has been implicated in a handful of rare pediatric diseases, but their role in normal aging has received far less attention than the mitochondrial-decline hypothesis. The C. elegans work suggests that peroxisomal insufficiency contributes to the age-related loss of the ability to shift between lipid and glucose fuels — one of the metabolic phenotypes most consistently associated with frailty in humans.

Because peroxisomal biogenesis and function are regulated by well-characterized transcription factors (PPARα in particular), the finding points to a druggable pathway. Existing PPARα agonists such as fibrates are already used clinically for dyslipidemia, and their potential repurposing as geroprotective agents is a natural follow-on question, though direct extrapolation from worm to human requires substantial validation.

The broader theme is that aging is turning out to be less a single-organelle story than an integrated failure of multiple energy-handling systems. Mitochondria remain central, but this week’s work makes the case that peroxisomal biology deserves a proportional share of geroscience research attention, particularly as the field looks for additional metabolic levers beyond the ones already being pursued.

Source: Nature Aging